Changes in Hepatic Steatosis Before and After Direct-Acting Antiviral Treatment in People With HIV and Hepatitis C Coinfection
When assessed by CAP, HS was unaffected by DAA treatment and steadily increased over time. In contrast, HSI did not appear to reflect changes in HS, with the decrease during treatment likely related to resolution of hepatic inflammation. Ongoing HS may pose a risk for liver disease in coinfected people cured of HCV.
Authors
- Sharon Walmsley (ORCID: https://orcid.org/0000-0002-3959-5692)
- Curtis Cooper (ORCID: https://orcid.org/0000-0002-3368-3499)
- Mark Hull
- Marina B. Klein (ORCID: https://orcid.org/0000-0002-3063-8430)
- Jim Young (ORCID: https://orcid.org/0000-0002-4314-3007)
- Shouao Wang
- Giada Sebastiani (ORCID: https://orcid.org/0000-0003-2655-8283)
- Esther Truscello
Institutions
- University Health Network (CA)
- Canadian Institutes of Health Research (CA)
- University of Toronto (CA)
- Ottawa Hospital (CA)
- McGill University Health Centre (CA)
- Maastricht University (NL)
- Department of Health (TW)
- AIDS Vancouver (CA)
- Ottawa Hospital Research Institute (CA)
- McGill University (CA)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1093/infdis/jiae487
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Canada Research Chairs
- Canadian Institutes of Health Research
- Fonds de Recherche du Québec - Santé